MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$2,966,336
EPS
-$0.73
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Sales
-
820,188
1,120,121
1,888,838.5*
Cost of sales
-
635,994
716,962
922,372*
Gross profit
-
184,194
403,159
966,466.5*
Research and development
1,022,630
630,636
581,612
540,380*
General and administrative
1,742,016
1,621,095
1,532,015
5,906,910.5*
Amortization and depreciation
51,707
53,201
53,202
49,102*
Foreign exchange loss
-23,168
18,136
-56,994
-7,117.75*
Total operating expenses
2,839,521
2,286,796
2,223,823
6,503,510.25*
Interest and other income
47,770
74,379
93,765
-15,400*
Finance expense
-
-
-
92,887.25*
Net loss from continuing operations before taxes
-2,791,751
-2,028,223
-1,726,899
-5,645,331
Net loss from continuing operations
-2,791,751
-
-
-
Income (loss) from discontinued operations
-174,585
-
-
-
Loss from discontinued operations
-174,585
-
-
-
Net loss
-2,966,336
-2,028,223
-1,726,899
-5,645,331
Basic EPS
-0.73
-0.51
-0.44
-5.784
Diluted EPS
-0.73
-0.51
-0.44
-5.784
Basic Average Shares
4,048,209
3,954,549
3,954,549
975,985*
Diluted Average Shares
4,048,209
3,954,549
3,954,549
975,985*
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$2,966,336
Net loss from
continuing operations
-$2,791,751
Loss from
discontinued operations
-$174,585
Net loss from
continuing operations...
-$2,791,751
Income (loss) from
discontinued operations
-$174,585
Interest and other income
$47,770
Total operating
expenses
$2,839,521
General and
administrative
$1,742,016
Research and development
$1,022,630
Amortization and
depreciation
$51,707
Foreign exchange loss
-$23,168
Buy us a coffee
InMed Pharmaceuticals Inc. (INM)
InMed Pharmaceuticals Inc. (INM)